Phase 2, Open-label, Multicenter, Dose Escalation Study of Venetoclax and Dexamethasone in Combination with Carfilzomib in Subjects with Relapsed or Refractory Multiple Myeloma

Grants and Contracts Details

StatusFinished
Effective start/end date1/4/17 → 5/20/22

Funding

  • AbbVie Incorporated: $232,603.00